The February 10, 2016 article by Hortobagyi et al entitled “Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2” (J Clin Oncol 34:419–426, 2016) was published online October 26, 2015, with errors of omission in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Burris’ COIs were given as:

Howard A. Burris III

No relationship to disclose

They should have read as:

Howard A. Burris

Employment: HCA Healthcare/Sarah Cannon

Leadership: HCA Healthcare/Sarah Cannon

Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon

Consulting or Advisory Role: Mersana Therapeutics (Inst), AstraZeneca (Inst), Janssen (Inst), Novartis (Inst), Roche/Genentech (Inst), TG Therapeutics (Inst), MedImmune (Inst), Bristol-Myers Squibb (Inst), Astellas (Inst), Baxter Healthcare (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), Bayer Healthcare (Inst), Merck (Inst), GlaxoSmithKline (Inst), Pfizer (Inst),

Vertex (Inst), Gilead Sciences (Inst), Sanofi-Aventis (Inst), Chugai (Inst), E.R. Squibb & Sons (Inst), Eisai (Inst), Grifols USA (Inst), Incyte (Inst), Medivation (Inst), Otsuka (Inst), Amgen (Inst), Ipsen (Inst), Prostrakan (Inst), Tolmar (Inst), Genzyme (Inst), Helsinn (Inst), Spectrum Pharmaceuticals (Inst)

Research Funding: Roche/Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), Mersana Therapeutics (Inst), AstraZeneca (Inst), MedImmune (Inst), MacroGenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), AbbVie (Inst), Bayer (Inst), Celldex Therapeutics (Inst), Merck (Inst), Celgene (Inst), Agios Pharmaceuticals (Inst), Jounce Therapeutics (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Immunocore (Inst), Takeda (Inst), Millennium (Inst), BioMed Valley Discoveries (Inst), Pfizer (Inst), TG Therapeutics (Inst), Loxo (Inst), Vertex (Inst), eFFECTOR Therapeutics (Inst), Janssen (Inst), Gilead Sciences (Inst), Valent Technologies (Inst), H3 Biomedicine (Inst), OncoMed (Inst), Regeneron (Inst), Sanofi (Inst), Medivation (Inst), Mirna Therapeutics (Inst), Amgen (Inst), Ventana Medical Systems (Inst), Acerta Pharma (Inst), Exelixis (Inst), Array BioPharma (Inst), StemCentrx (Inst), BIND Therapeutics (Inst)

This has been corrected as of January 7, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02265>

The March 10, 2016, article by Long et al entitled “Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib” (J Clin Oncol 34:871–878, 2016) was published online January 25, 2016, with errors of omission in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Burris’ COIs were given as:

Howard A. Burris III

No relationship to disclose

They should have read as:

Howard A. Burris

Employment: HCA Healthcare/Sarah Cannon

Leadership: HCA Healthcare/Sarah Cannon

Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon

Consulting or Advisory Role: Mersana Therapeutics (Inst), AstraZeneca (Inst), Janssen (Inst), Novartis (Inst), Roche/Genentech (Inst), TG Therapeutics (Inst), MedImmune (Inst), Bristol-Myers Squibb (Inst), Astellas (Inst), Baxter Healthcare (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), Bayer Healthcare (Inst), Merck (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Vertex (Inst), Gilead Sciences (Inst), Sanofi-Aventis (Inst), Chugai

(Inst), E.R. Squibb & Sons (Inst), Eisai (Inst), Grifols USA (Inst), Incyte (Inst), Medivation (Inst), Otsuka (Inst), Amgen (Inst), Ipsen (Inst), Prostrakan (Inst), Tolmar (Inst), Genzyme (Inst), Helsinn (Inst), Spectrum Pharmaceuticals (Inst)

Research Funding: Roche/Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), Mersana Therapeutics (Inst), AstraZeneca (Inst), MedImmune (Inst), MacroGenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), AbbVie (Inst), Bayer (Inst), Celldex Therapeutics (Inst), Merck (Inst), Celgene (Inst), Agios Pharmaceuticals (Inst), Jounce Therapeutics (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Immunocore (Inst), Takeda (Inst), Millennium (Inst), BioMed Valley Discoveries (Inst), Pfizer (Inst), TG Therapeutics (Inst), Loxo (Inst), Vertex (Inst), eFFECTOR Therapeutics (Inst), Janssen (Inst), Gilead Sciences (Inst), Valent Technologies (Inst), H3 Biomedicine (Inst), OncoMed (Inst), Regeneron (Inst), Sanofi (Inst), Medivation (Inst), Mirna Therapeutics (Inst), Amgen (Inst), Ventana Medical Systems (Inst), Acerta Pharma (Inst), Exelixis (Inst), Array BioPharma (Inst), StemCentrx (Inst), BIND Therapeutics (Inst)

This has been corrected as of January 7, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02267>